This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Hypertension	Angiotensin- converting enzyme (ACE); endothelin converting enzyme 1 (ECE1); membrane metallo- endopeptidase (MME; NEP; CD10)	<i>In vitro</i> and rat studies suggest that dual ACE and ECE1 inhibitors could help treat hypertension. An <i>in vitro</i> screen identified a phosphinic tripeptide molecule that inhibited Ace and Ece-1. In a rat model of hypertension, the compound reduced mean arterial blood pressure by up to 15% compared with no treatment. Future studies could include designing nonpeptide mimetics of the lead compound.	Patented by Servier and the Commission for Atomic Energy; licensing status unavailable	Jullien, N. <i>et al. J. Med. Chem.</i> ; published online Nov. 9, 2009; doi:10.1021/jm9010803 Contact: Vincent Dive, Commission for Atomic Energy, Gif-sur-Yvette Cedex, France e-mail: vincent.dive@cea.fr
		SciBX 2(45); doi:10.1038/scibx.2009.1662 Published online Nov. 19, 2009		